Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesVincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Childrens Oncology Group Study d9803
Journal of Clinical Oncology, 09/29/09
Arndt CAS et al. – For intermediate-risk RMS, VAC/VTC does not significantly improve FFS compared with VAC.
Methods- Patients randomly assigned to 39 weeks of VAC versus VAC/VTC
- Local therapy began after week 12
- Patients with parameningeal RMS with intracranial extension (PME) treated with VAC and immediate x-ray therapy
- Primary study end point was failure-free survival (FFS)
- Study designed with 80% power (5% 2-sided level) to detect an increase in 5-year FFS from 64% to 75% with VAC/VTC
- 617 eligible patients entered onto study
- 264 randomly assigned to VAC and 252 to VAC/VTC; 101 PME patients were nonrandomly treated with VAC
- Treatment strata were embryonal RMS, stage 2/3, group III (33%); embryonal RMS, group IV, less than age 10 years (7%); alveolar RMS or undifferentiated sarcoma (UDS), stage 1 or group I (17%); alveolar RMS/UDS (27%); and PME (16%)
- Median follow-up of 4.3 years, 4-year FFS was 73% with VAC and 68% with VAC/VTC
- Frequency of second malignancies was similar between two treatment groups
Today in Pediatric Heme/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia
Journal of Clinical Oncology, 11/09/09
Medulloblastoma in childhood: revisiting intrathecal therapy in infants and children
Cancer Chemotherapy and Pharmacology, 10/29/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Activity of fulvestrant in HER2-overexpressing advanced breast cancer
Annals of Oncology, 11/06/09
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer
Journal of Clinical Oncology, 11/02/09
Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia
Journal of Clinical Oncology, 11/09/09
Today in Soft Tissue/Sarcoma...keeping you current
Receive free subspecialty "5-minute updates" via email
Randomized Trial and Pharmacokinetic Study of Pegfilgrastim versus Filgrastim after Dose-Intensive Chemotherapy in Young Adults and Children with Sarcomas
Clinical Cancer Research, 11/20/09
Incidence and Correlates of Radiation Dermatitis in Children and Adolescents Receiving Radiation Therapy for the Treatment of Paediatric Sarcomas
Clinical Oncology, 11/12/09
Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin-containing chemotherapy
Annals of Oncology, 11/04/09
Sponsor
Article Search
Sponsor
Sponsor